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VMMC and Safdarjung Hospital, New Delhi, India
A 33-year-old non-smoking male who was a farmer by trade and had no other comorbidities presented 
with complaints of shortness of breath, left sided chest pain and dry cough which had bothered him for over 
the past 7 days. Past history was insignificant. The patient had tachycardia, tachypnoea (30/min) and oxygen 
saturation of 88%. There was no clubbing or cyanosis. Chest examination was suggestive of bilateral decreased 
air entry. A CT examination of the chest was performed (Figure 1A, B). Bilateral intercostal chest tubes were 
inserted and the patient was given oxygen support. Due to refusal by the patient to perform a surgical lung 
biopsy, a trans-bronchial lung biopsy (TBLB) (Figure 1C, D) was performed. The patient had bilateral leaks in 
intercostal chest tubes. When negative suction to both sides was applied, successful cessation of the air leaks 
was observed.
As the CT thorax was suggestive of bilateral pneumothorax with underlying cysts predominantly in 
upper and mid zones, few nodular opacities, and sparing of costophrenic recess, a provisional diagnosis of 
pulmonary Langerhans cell histiocytosis (pLCH) was suspected.  Transbronchial lung biopsy was suggestive 
of interstitial fibrosis with a collection of Langerhans cells that had prominent nuclei with CD1a positivity. 
Thus, the diagnosis of pLCH was made on the basis of clinico-radiological, histopathological and immunohi-
stochemical grounds.  
According to an expert panel, definitive diagnosis of pLCH requires either microscopic evidence of Langerhans 
cells with CD1a positivity or Birbeck granule visualization on electron microscopy [1].
A detailed history of polyuria, polydipsia, headache, bone pains, diarrhoea, weight loss, enlarged lymph 
nodes, oral/skin lesions and/or genital ulcers was negative. Liver function tests, a routine examination of 
urine for sugar and proteins, ultrasonography of the abdomen and pelvis, a CT examination of the head, and 
a skeletal scintigram (bone scan) were all normal. 
Figure 1. A, B. Contrast enhanced CT chest showing bilateral pneumothorax with bilateral well defined, irregular, thin walled bizarre cysts 
of variable shape and size with a predominance in the upper and middle lobes. There is sparing of the costophrenic angles; C. Transbronchial 
lung biopsy (10 × magnification in hematoxylin and eosin stain) showing sheets of Langerhans cells with prominent nucleoli which were 
positive for CD1a (D)
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pLCH has an association with smoking in 95% of patients. However, it has been reported in non- smokers 
also [2, 3]. Our patient had never smoked tobacco or marijuana. This rarity may be a cause of the delayed 
diagnosis.
Smoking cessation has been shown to be partially effective in preventing progression [4], but it is not always 
beneficial [5]. Treatment in non-smokers can be given if the patient is symptomatic.  Steroids have been shown 
to be beneficial in pLCH, especially in isolated pulmonary involvement in adults. Cladribine has also been tried 
in non-responsive cases [6]. Cases of pneumothorax are treated with standard measures which include, among 
others, intercostal drainage via tubes with pleurodesis. Pleurectomy should be avoided as patients will eventually 
need a lung transplant in progressive cases. Our patient is on oral 1 mg/kg prednisolone therapy as recommended 
by an expert panel [1]. Watchful waiting was not preferred as our patient continued to be symptomatic. However, 
in view of an absence of any randomized trials for steroid therapy in pLCH, the therapy must be weighed on the 
basis of risk-benefit ratio as patients with spontaneous remission have also been reported [1]. The patient has been 
counseled for the future need of a lung transplant. Five-year survival has been reported to be more than 50%, but 
post-transplant recurrence has also been shown in 20% of patients [6].
Thus, it is prudent to search for pLCH even in non-smoking young adult males, particularly in patients 
with collaborative radiological and pathological evidence. This is true because, even in such rare cases, an early 
diagnosis can help in early treatment and in providing an improved prognosis.
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